The Current Ratio as of November 2024 (TTM) for Cassava Sciences, Inc. (SAVA) is 4.07

According to Cassava Sciences, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 4.07. This represents a change of -30.93% compared to the average of 5.89 of the last 4 quarters.

Cassava Sciences, Inc. (SAVA) Historical Current Ratio (quarterly & annually)

How has SAVA Current Ratio performed in the past?

The mean historical Current Ratio of Cassava Sciences, Inc. over the last ten years is 26.35. The current 4.07 Current Ratio has changed 1.44% with respect to the historical average. Over the past ten years (40 quarters), SAVA's Current Ratio was at its highest in in the March 2021 quarter at 107.08. The Current Ratio was at its lowest in in the March 2024 quarter at 1.74.

Cassava Sciences, Inc. (SAVA) Current Ratio by Quarter and Year

Discovering the peaks and valleys of Cassava Sciences, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Cassava Sciences, Inc. (SAVA) Average Current Ratio

How has SAVA Current Ratio performed in the past?

The current Current Ratio of Cassava Sciences, Inc. (SAVA) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

Cassava Sciences, Inc. (SAVA) Current Ratio vs. Peers

How is SAVA’s Current Ratio compared to its peers?

Cassava Sciences, Inc.’s Current Ratio is greater than Annovis Bio, Inc. (1.24), greater than Axsome Therapeutics, Inc. (2.48), greater than Reviva Pharmaceuticals Holdings, Inc. (0.41), greater than Seres Therapeutics, Inc. (1.38), less than Anavex Life Sciences Corp. (12.04), greater than INmune Bio, Inc. (2.59), greater than BioVie Inc. (2.57), greater than Cognition Therapeutics, Inc. (3.07), greater than CureVac N.V. (2.29), greater than Reata Pharmaceuticals, Inc. (3.21), less than Krystal Biotech, Inc. (9.50), less than Vir Biotechnology, Inc. (8.94), greater than Propanc Biopharma, Inc. (0.01), greater than Exelixis, Inc. (3.93), greater than TG Therapeutics, Inc. (3.58), less than Viking Therapeutics, Inc. (36.47), less than Madrigal Pharmaceuticals, Inc. (5.98), greater than BioXcel Therapeutics, Inc. (2.35),

Build a custom stock screener for Cassava Sciences, Inc. (SAVA) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Cassava Sciences, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Cassava Sciences, Inc. (SAVA) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Cassava Sciences, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.